Cristal Therapeutics applies three distinct and interconnected technologies together with biologic insight to improve the therapeutic profile of our partners’ programs in development. Based on over 10 years of realworld experience, Cristal’s CliCr®, CriPec® and CriVac® technologies provide superior conjugation, enhancetarget specificity and engender highly selective immune responses, thereby increasing efficacy and reducing toxicity. The company aims to be the partner of choice for overcoming challenges and enabling the full potential of ADCs, immuno-oncology treatments, vaccines, among a broad range of therapeutics, tuned to modality and indication.